Untitled

[ritedose]

Ritedose Launches RISE Program with New Partnerships

Ritedose partners with Verona Pharma to manufacture Ohtuvayre—a first-in-class inhaled COPD drug approved in 2024, aiming to transform respi

To meet a need for demanding company roles, The Ritedose Corporation (Ritedose) partnered with inSpring and Benedict College to develop RISE, a workforce initiative for international STEM students at the Historically Black College and University (HBCU).

[ritedose]

Ritedose and Newberry College Launch Pharmaceutical Program

Ritedose and Newberry College launch a pharmaceutical program—preparing students for careers in South Carolina’s life sciences industry.

In response to the growing demand for skilled professionals in South Carolina’s life sciences sector, The Ritedose Corporation has partnered with Newberry College to launch a new Pharmaceutical Manufacturing program, set to begin in the summer of 2025. This collaboration combines the strengths of both institutions to prepare students for careers in one of the state’s most dynamic industries.

[ritedose]

Ritedose Expands 1,000 Hours of Purpose Initiative

COLUMBIA, S.C. – March 6, 2025 - The Ritedose Corporation (Ritedose) announces a groundbreaking new volunteer program: 1,000 Hours of Purpos

“1,000 Hours of Purpose” is a year-long initiative that provides Ritedose employees with the opportunity to dedicate their time, skills and resources to support meaningful causes across the Midlands. Under this new program, Ritedose is collaborating with United Way of the Midlands and donating 1,000 hours of employee time to support various local organizations that are addressing basic human needs like hunger and housing.

[ritedose]

Ritedose Adds 7th Line to Support COPD Drug Packaging

COLUMBIA, S.C. April 16, 2025 – Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation,

Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) is adding a seventh Syntegon packaging line to its state-of-the-art manufacturing facility that will double the company’s capacity. Ritedose expects the packaging line to be in service by early summer of 2025. The automated system is currently undergoing Site Acceptance Testing at The Ritedose facility.

[ritedose]

Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*—Addressing Nationwide Shorta

COLUMBIA, SC May 20, 2025 —Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the largest sterile contract develop

Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the largest sterile contract development manufacturing organization (CDMO) in the US specializing in aseptic unit-dose medication production using Blow-Fill-Seal (BFS) technology, received US Food and Drug Administration (FDA) approval for manufacturing and distributing generic Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*

[ritedose]

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park | The Ritedose Corporation

COLUMBIA, SC, June 18, 2025 – The Ritedose Corporation, a leading pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technolog

The Ritedose Corporation, a leading pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technology, today unveiled its new distribution and logistics facility at Performance Park during a ribbon-cutting ceremony. The grand opening event included Ritedose CEO Jody Chastain, state and county officials, community leaders, and key partners in the life sciences ecosystem.